When a pathology report says 'melanoma,' the stakes are high. How confident are you in the diagnosis? Should you order gene expression profiling for better prognostic insights—or is it overrated?

Join the Derms on Drugs as we dig into the challenges of melanoma diagnosis and management. This week, we’re thrilled to feature Dr. Whitney High from the University of Colorado, the best-of-the-best dermatopathology expert, to share evidence-based answers with the Derms on Drugs flare our listeners expect.  

Derms on Drugs is brought to you by ⁠⁠Scholars in Medicine.⁠

Resource links for this episode are available at ⁠Scholars in Medicine⁠.
1.  Society of Surgical Oncology Consensus Statement: Assessing the Evidence for and Utility of Gene Expression Profiling of Primary Cutaneous Melanoma

2.  31-GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort

3.  CLO25-055: Metastasis-Free Survival Prediction With the 40-Gene Expression Profile Test in Patients With Cutaneous Squamous Cell Carcinoma Risk Stratified According to the National Comprehensive Cancer Network Guidelines

4.  CGE25-104: The 31-GEP Identifies Patients With Early-Stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-Specific and Overall Mortality